SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Evofem at Critical Stretch with Potential New Birth Control
BIOTECH: Contraceptive Gel Is Part of CEO's Health Mission for WomenEvofem Biosciences wants to be the next big thing in birth control. After a long road, the San Diego biotech finds itself in a pivotal stretch.Pursuing ‘Untapped Biology,’ Boundless Bio Lands $46.4M Funding Round
Boundless Bio Inc. emerged Sept. 19 with $46.4 million in funding and a claim to new territory: extrachromosomal DNA
Acadia Pharmaceuticals Plans $250M Stock Offering
Acadia Pharmaceuticals is planning to raise $250 million through a public stock offering.
$161B Market Seen in ‘Functional Foods’
HEALTH: Consumer Focus on Nutrition Drives Demand
More and more, San Diego-based food companies are placing focus on including functional ingredients in their “better for you” offerings.
DelMar Pharmaceuticals Relocates to San Diego
DelMar Pharmaceuticals has relocated from British Columbia to San Diego.
SGI-DNA Pulls in $25M Series A Round for DNA Printer
San Diego’s SGI-DNA, a spinout of Synthetic Genomics, has raised a $25 million series A round.
Company Has Instrument of Change for Dermatology
MEDICINE: DermTech’s Patch May Change Skin Cancer Diagnostics
Could that suspicious mole be cancerous? DermTech wants doctors to reach for a patch, not a scalpel.
SDBJ INSIDER: The Wait May Soon Be Over
Obalon Therapeutics Inc. announced Dr. Helmuth Billy as medical director for its first company-owned weight-loss treatment center.
Turning Point Therapeutics Raises $202.5M in Follow-On Offering
BIOTECH: Cancer Drug Developer Plans To Build Its Pipeline
After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market.
Tocagen’s Brain Cancer Therapy Fails Clinical Trial
Shares of Tocagen fell Sept. 12 after its brain cancer therapy failed a late-stage clinical trial.
Turning Point Therapeutics Raises $202.5M in Follow-On Offering
The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a share.
Capping Off An Unusual Pact, GlaxoSmithKline Buys Sitari Pharmaceuticals
GlaxoSmithKline announced it will acquire San Diego’s Sitari Pharmaceuticals – a deal induced by an unusual pact.
Health Systems Try Ride-Sharing Solutions
MEDICINE: Getting Patients to Appointments or Home Is Goal
An increasingly common destination for Lyft and Uber drivers: San Diego hospitals.
Center Is S.D.’s ‘First Academic-Industry Drug Discovery Incubator’
UC San Diego Offering Space to Pharma Industry To Help Develop Drugs
UC San Diego Moores Cancer Center is offering up space on its campus to the pharmaceutical industry in a bid to translate research into medicines for cancer patients.
Cidara’s Deal for Antifungal Drug Could Be Worth $568M+
Mundipharma’s Backing Will Extend Runway, Provide Well-Positioned Support
Clinical trial results have yielded a major payout for Cidara Therapeutics, a San Diego company developing an antifungal drug.
Acadia’s Stock Shoots Up After Late-Stage Results
Shares of Acadia Pharmaceuticals rocketed up 63% on Sept. 9 after its drug in a late-stage clinical trial achieved “robust statistical superiority” over a placebo for dementia-related psychosis.
Prev Next